Cargando…

Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis

A 78-year-old woman visited the emergency department with complaints of progressively worsening abdominal pain for a week. Nausea and vomiting started at the time of the visit. An abdominal contrast-enhanced CT (CECT) revealed a filling defect of portal vein, splenic vein and superior mesenteric vei...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Yuya, Yoshioka, Takashi, Senoh, Mayumi, Sunami, Kazuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700539/
https://www.ncbi.nlm.nih.gov/pubmed/31420420
http://dx.doi.org/10.1136/bcr-2018-228427
_version_ 1783444894997544960
author Yokota, Yuya
Yoshioka, Takashi
Senoh, Mayumi
Sunami, Kazuharu
author_facet Yokota, Yuya
Yoshioka, Takashi
Senoh, Mayumi
Sunami, Kazuharu
author_sort Yokota, Yuya
collection PubMed
description A 78-year-old woman visited the emergency department with complaints of progressively worsening abdominal pain for a week. Nausea and vomiting started at the time of the visit. An abdominal contrast-enhanced CT (CECT) revealed a filling defect of portal vein, splenic vein and superior mesenteric vein (SMV) which was diagnosed as portal vein and mesenteric venous thrombosis (MVT). Intravenous administration of unfractionated heparin was initiated. However, her symptoms did not improve, and she underwent surgical thrombectomy on the second day of hospitalisation. On the sixth day, CECT revealed the recurrence of thrombi in the portal vein, SMV and along the central venous catheters. We switched heparin to argatroban on the eighth day. After administering argatroban, CECT revealed that the thrombi had almost disappeared by the 40th day. In this case, argatroban was considered effective for heparin-resistant and surgery-resistant portal vein and MVT.
format Online
Article
Text
id pubmed-6700539
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67005392019-08-29 Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis Yokota, Yuya Yoshioka, Takashi Senoh, Mayumi Sunami, Kazuharu BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) A 78-year-old woman visited the emergency department with complaints of progressively worsening abdominal pain for a week. Nausea and vomiting started at the time of the visit. An abdominal contrast-enhanced CT (CECT) revealed a filling defect of portal vein, splenic vein and superior mesenteric vein (SMV) which was diagnosed as portal vein and mesenteric venous thrombosis (MVT). Intravenous administration of unfractionated heparin was initiated. However, her symptoms did not improve, and she underwent surgical thrombectomy on the second day of hospitalisation. On the sixth day, CECT revealed the recurrence of thrombi in the portal vein, SMV and along the central venous catheters. We switched heparin to argatroban on the eighth day. After administering argatroban, CECT revealed that the thrombi had almost disappeared by the 40th day. In this case, argatroban was considered effective for heparin-resistant and surgery-resistant portal vein and MVT. BMJ Publishing Group 2019-08-15 /pmc/articles/PMC6700539/ /pubmed/31420420 http://dx.doi.org/10.1136/bcr-2018-228427 Text en © BMJ Publishing Group Limited 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Yokota, Yuya
Yoshioka, Takashi
Senoh, Mayumi
Sunami, Kazuharu
Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title_full Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title_fullStr Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title_full_unstemmed Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title_short Successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
title_sort successful intravenous administration of argatroban in the management of heparin-resistant and surgery-resistant mesenteric vein thrombosis
topic Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700539/
https://www.ncbi.nlm.nih.gov/pubmed/31420420
http://dx.doi.org/10.1136/bcr-2018-228427
work_keys_str_mv AT yokotayuya successfulintravenousadministrationofargatrobaninthemanagementofheparinresistantandsurgeryresistantmesentericveinthrombosis
AT yoshiokatakashi successfulintravenousadministrationofargatrobaninthemanagementofheparinresistantandsurgeryresistantmesentericveinthrombosis
AT senohmayumi successfulintravenousadministrationofargatrobaninthemanagementofheparinresistantandsurgeryresistantmesentericveinthrombosis
AT sunamikazuharu successfulintravenousadministrationofargatrobaninthemanagementofheparinresistantandsurgeryresistantmesentericveinthrombosis